Introduction to Proceedings from a Conference on Newborn Screening for Nontreatable Disorders by Mehlman, Maxwell J.
Case Western Reserve University 
School of Law Scholarly Commons 
Faculty Publications 
2009 
Introduction to Proceedings from a Conference on Newborn 
Screening for Nontreatable Disorders 
Maxwell J. Mehlman 
Case Western University School of Law, maxwell.mehlman@case.edu 
Follow this and additional works at: https://scholarlycommons.law.case.edu/faculty_publications 
 Part of the Health Law and Policy Commons, and the Jurisprudence Commons 
Repository Citation 
Mehlman, Maxwell J., "Introduction to Proceedings from a Conference on Newborn Screening for 
Nontreatable Disorders" (2009). Faculty Publications. 7. 
https://scholarlycommons.law.case.edu/faculty_publications/7 
This Article is brought to you for free and open access by Case Western Reserve University School of Law Scholarly 
Commons. It has been accepted for inclusion in Faculty Publications by an authorized administrator of Case 
Western Reserve University School of Law Scholarly Commons. 
INTRODUCTION TO PROCEEDINGS 
FROM A CONFERENCE ON 
NEWBORN SCREENING FOR 
NONTREAT ABLE DISORDERS 
Maxwell J. Mehlman t 
Newborn screening began in the 1960's after physician Robert 
Guthrie developed a screening test for PKU, an autosomal recessive 
metabolic disorder that can be treated effectively if detected soon after 
birth. Guthrie also pioneered a method for collecting and transporting 
on special filter paper the blood samples used for screening, known as 
"Guthrie cards," and he insisted that the collection and analysis of the 
samples be performed by state public health officials. Massachusetts 
adopted newborn screening on a voluntary basis in 1962, but after 
President Kennedy's Advisory Committee on Mental Retardation 
recommended mandatory screening, states began to enact newborn 
screening as a legal requirement. By 1973, newborn screening was 
compulsory in 43 states. Now it is universal. 
Newborn screening was justified originally on the basis that it 
could detect disorders that could be successfully treated or mitigated 
only if caught early in life. The development of faster and cheaper 
technologies such as tandem mass spectrometry and microchip arrays, 
however, enable programs to screen for far greater numbers of disor-
ders, including many for which no readily effective treatments pres-
ently exist. Screening for these nontreatable disorders can be bene-
ficial, in that it could spare families years of uncertainty once symp-
toms emerged; alert them to be on the watch for new discoveries that 
could provide their children with treatment; provide children with 
adjunctive if not curative interventions; and facilitate participation of 
the children in research on their disorders. Yet some public health 
advocates offer an additional rationale for screening for nontreatable 
disorders: that it can serve as a valuable tool in family planning. One 
recent article explains, for example: "Arguments for considering 
broader benefits from the early diagnosis that only newborn screening 
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can provide include . . . knowledge on which to base reproductive 
decision-making years before a disease would be diagnosed for the 
affected child .... " 1 In short, nontreatable disorders would be included 
in the screening panel in part in order to discourage parents from giving 
birth to additional children with genetic disorders, and the authors make 
it clear that one reason for this is to prevent these children from becom-
ing a burden on society. 
The question is whether this would be appropriate. In virtually all 
states, newborn screening is compulsory. In 2005, for example, the 
Nebraska Supreme Court rejected a constitutional challenge to newborn 
screening based on religious grounds.2 Government-mandated health 
programs are justified historically on the basis as an exercise of the 
state's police power aimed at preventing the spread of contagion. On 
this basis, for example, the Supreme Court in 1905 sustained the consti-
tutionality of compulsory vaccination. 3 But unless giving birth to a 
child with genetic abnmmalities is regarded as "spreading disease," it 
cannot be justified on this basis. Moreover, mandatory screening by the 
state for the purpose of preventing the birth of children with birth 
defects may strike some as bearing too close a resemblance to the 
discredited, state-sponsored eugenics programs of the early and mid-
201h century. Indeed, the only constitutional precedent for it is the 
infamous 1927 case of Buck v. Bell,4 in which Justice Holmes upheld 
the Virginia law that permitted forced sterilization of the supposedly 
"feeble-minded." This law became the model for the Nazi eugenics 
legislation enacted by the Reichstag following Hitler's election as 
Chancellor of Gennany. 
On May 2, 2008, the Law-Medicine Center, with funding support 
from the Inamori International Center for Ethics and Excellence and 
the Center for Genetic Research Ethics and Law, both here at Case 
Western Reserve University, held a workshop to consider the ethical, 
legal, and social issues raised by the prospect of newborn screening 
for nontreatable disorders. The workshop, the first of its kind, took 
place in conjunction with a conference on ethical, legal, and social 
issues in human genetics sponsored by the National Human Genome 
Research Institute at the National institutes of Health. This issue of 
Health Matrix presents the papers commissioned for this workshop. 
The papers are by five of the leading experts in the field: Donald B. 
Bailey, Distinguished Fellow, RTI (Research Triangle Institute) Inter-
1 Duane Alexander (NIH) & Peter C. van Dyck (HRSA), A Vision of the 
Future of Newborn Screening, 117 PED!ATRJCS S350, 352 (2006). 
2 Douglas County v. Anaya, 694 N.W.2d 601 (Neb. 2005). 
3 Jacobson v. Massachusetts, 197 U.S. 11 (1905). 
4 Buck v. Bell, 274 U.S. 200 (1927). 
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national; Jeffrey R. Botkin, MD, MPH; Professor of Pediatrics, Uni-
versity ofUtah School ofMedicine; Ellen W. Clayton, MD, JD; Rosa-
lind E. Franklin Professor of Genetics and Health Policy at Vanderbilt 
University; R. Rodney Howell, MD; Professor of Pediatrics, Miller 
School of Medicine, University of Miami, Florida; and Marvin Na-
towicz, MD, PhD; Pediatric Geneticist; Clinical Pathologist; Vice 
Chairman, Genomic Medicine Institute and Neurologist at the Cleve-
land Clinic. 
